Status:
COMPLETED
Interpretation of Serological Tests in the Diagnosis of Celiac Disease: Anti-deamidated Gliadin Peptide Antibodies Revisited
Lead Sponsor:
CHU de Reims
Conditions:
Celiac Disease
Eligibility:
All Genders
Brief Summary
Celiac disease is an autoimmune disorder characterized by a chronic inflammation of the small bowel mucosa, triggered by the ingestion of gluten-containing grains. The diagnosis of celiac disease was...
Detailed Description
The aim was to assess the clinical relevance of anti-deamidated gliadin peptide antibodies compared with the other common celiac markers.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- \- patients attending the Reims University Hospitals, for whom serological tests for celiac disease were prescribed between 1 april 2012 to 31 december 2014
Exclusion
Key Trial Info
Start Date :
January 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
2026 Patients enrolled
Trial Details
Trial ID
NCT03320811
Start Date
January 1 2015
End Date
January 1 2016
Last Update
October 25 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Damien JOLLY
Reims, France